Lena Wischhof1, Michael Koch. 1. Department of Neuropharmacology, Brain Research Institute, Center for Cognitive Sciences, University of Bremen, PO Box 330440, 28334 Bremen, Germany. lena_wischhof@yahoo.de
Abstract
RATIONALE: Overactivation of serotonin (5-hydroxytryptamine, 5-HT)(2A) receptors causes impulsivity and attentional deficits. Since 5-HT(2A) receptors are known to entertain antagonistic interactions with metabotropic glutamate (mGlu)2/3 receptors, this interaction may provide an alternative target for a novel class of antipsychotics. OBJECTIVES/ METHODS: The study characterizes interactions between 5-HT(2A) and mGlu2/3 receptors implicated in impulse control. Hooded Lister rats were trained in a 5-choice serial reaction time task (5-CSRTT) and treated with the 5-HT(2A/2C) receptor agonist (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropan hydrochloride (DOI, 0.1 mg/kg) and the mGlu2/3 receptor agonist LY379268 (1 mg/kg). In addition, associated drug-induced changes in neuronal activity were assessed via c-Fos immunoreactivity (Fos IR), and co-localization of c-Fos and GABAergic markers was detected using double immunofluorescence labeling. RESULTS: Systemic DOI caused impulsive overresponding that was attenuated in animals pre-treated with LY379268. LY379268 itself had no significant effect on the rats' performance in the 5-CSRTT. DOI enhanced Fos IR within fronto-cortical and limbic brain structures, and this effect was blocked by LY379268 pre-treatment. Double immunofluorescence labeling showed a specific co-localization of DOI-elicited Fos IR with GABAergic (GAD(67)-positive) cells lacking the calcium-binding protein parvalbumin while LY379268 increased Fos IR in GABAergic and non-GABAergic cells. CONCLUSION: Our results suggest that impulsivity is possibly due to a primary increase in Glu transmission mediated via 5-HT(2A) receptor activation. Thus, mGlu2/3 receptor agonists might have some potential for treating motor impulsivity-related impairments while their cognitive enhancing effects were not confirmed in this study.
RATIONALE: Overactivation of serotonin (5-hydroxytryptamine, 5-HT)(2A) receptors causes impulsivity and attentional deficits. Since 5-HT(2A) receptors are known to entertain antagonistic interactions with metabotropic glutamate (mGlu)2/3 receptors, this interaction may provide an alternative target for a novel class of antipsychotics. OBJECTIVES/ METHODS: The study characterizes interactions between 5-HT(2A) and mGlu2/3 receptors implicated in impulse control. Hooded Lister rats were trained in a 5-choice serial reaction time task (5-CSRTT) and treated with the 5-HT(2A/2C) receptor agonist (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropan hydrochloride (DOI, 0.1 mg/kg) and the mGlu2/3 receptor agonist LY379268 (1 mg/kg). In addition, associated drug-induced changes in neuronal activity were assessed via c-Fos immunoreactivity (Fos IR), and co-localization of c-Fos and GABAergic markers was detected using double immunofluorescence labeling. RESULTS: Systemic DOI caused impulsive overresponding that was attenuated in animals pre-treated with LY379268. LY379268 itself had no significant effect on the rats' performance in the 5-CSRTT. DOI enhanced Fos IR within fronto-cortical and limbic brain structures, and this effect was blocked by LY379268 pre-treatment. Double immunofluorescence labeling showed a specific co-localization of DOI-elicited Fos IR with GABAergic (GAD(67)-positive) cells lacking the calcium-binding protein parvalbumin while LY379268 increased Fos IR in GABAergic and non-GABAergic cells. CONCLUSION: Our results suggest that impulsivity is possibly due to a primary increase in Glu transmission mediated via 5-HT(2A) receptor activation. Thus, mGlu2/3 receptor agonists might have some potential for treating motor impulsivity-related impairments while their cognitive enhancing effects were not confirmed in this study.
Authors: S Mobini; S Body; M-Y Ho; C M Bradshaw; E Szabadi; J F W Deakin; I M Anderson Journal: Psychopharmacology (Berl) Date: 2002-01-25 Impact factor: 4.530
Authors: Marcel M van Gaalen; Reinhild J Brueggeman; Patricia F C Bronius; Anton N M Schoffelmeer; Louk J M J Vanderschuren Journal: Psychopharmacology (Berl) Date: 2006-04-25 Impact factor: 4.530
Authors: Latham H L Fink; Noelle C Anastasio; Robert G Fox; Kenner C Rice; F Gerard Moeller; Kathryn A Cunningham Journal: Neuropsychopharmacology Date: 2015-02-10 Impact factor: 7.853
Authors: Adam L Halberstadt; Jochem V F van der Zee; Muhammad Chatha; Mark A Geyer; Susan B Powell Journal: Psychopharmacology (Berl) Date: 2018-11-17 Impact factor: 4.530
Authors: Noelle C Anastasio; Sonja J Stutz; Latham H L Fink; Sarah E Swinford-Jackson; Robert M Sears; Ralph J DiLeone; Kenner C Rice; F Gerard Moeller; Kathryn A Cunningham Journal: ACS Chem Neurosci Date: 2015-07-07 Impact factor: 4.418
Authors: Bastiaan van der Veen; Sampath K T Kapanaiah; Kasyoka Kilonzo; Peter Steele-Perkins; Martin M Jendryka; Stefanie Schulz; Bosiljka Tasic; Zizhen Yao; Hongkui Zeng; Thomas Akam; Janet R Nicholson; Birgit Liss; Wiebke Nissen; Anton Pekcec; Dennis Kätzel Journal: Commun Biol Date: 2021-06-02